Drug Trial Radar · NCT06908304
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Last checked: Nov 20, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Dec 8, 2025
Primary completion
Jul 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Maia BiotechnologyIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.
Conditions
- Carcinoma, Non-Small -Cell Lung
Interventions
6-Thio-2'-DeoxyguanosineDrug
small molecule telomere targeting agent
CemiplimabDrug
programmed cell death protein 1 (PD-1) inhibitor
DocetaxelDrug
Chemotherapy drug; inhibits cell division by stabilizing microtubules. Used for breast, lung, and prostate cancers.
VinorelbineDrug
Chemotherapy drug; disrupts microtubule formation, inhibiting cell division. Used for non-small cell lung cancer and breast cancer.
Gemcitabine aloneDrug
Chemotherapy drug; inhibits DNA synthesis. Used for pancreatic, lung, breast, and ovarian cancers.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Within 2 Years
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Centrum Medyczne Pratia
Poznan, Poland · Recruiting
Oncolab S.R.L.
Craiova, Romania · Recruiting
Spitalul Clinic Municipal de Urgenta Timisoara/ Clinica de Oncologie Medicala
Timișoara, Romania · Recruiting
Changhua Christian Hospital (CCH)
Changhua, Taiwan · Recruiting
Taipei Tzu Chi Hospital
Chiayi City, Taiwan · Recruiting
Chang-Gung Memorial Hospital - KaoHsiung
Kaohsiung City, Taiwan · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
Kaohsiung City, Taiwan · Recruiting
Chung Shan Medical University Hospital (CSMUH)
Taichung, Taiwan · Recruiting
Taipei Medical University Hospital (TMUH)
Taipei, Taiwan · Recruiting
Tri-Service General Hospital
Taipei, Taiwan · Recruiting
Chang-Gung Memorial Hospital - Linko
Taoyuan City, Taiwan · Recruiting
Medicalpark Hastanesi
Adana, Turkey (Türkiye) · Recruiting
Liv Hospital
Ankara, Turkey (Türkiye) · Recruiting
Göztepe Süleyman Yalçın Şehir Hastanesi
Istanbul, Turkey (Türkiye) · Recruiting
İstinye University
Istanbul, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.